KPMG is working with some of the smartest and most innovative players in the life sciences sector from around the world. We brought together industry leaders and our experts from around the world to discuss the future of the pharmaceutical, biomedical, and medical device industries. This virtual summit will help you share different perspectives and explore new approaches to help chart a future course.

Explore the summit

Session 1 Industry Outlook: The dynamic new reality  Session 2 Modern technology that is reshaping the life sciences industry
Session 3 Social trust in life sciences is vital to help people and planet thrive Session 4 Dealing in an era of fast evolving innovation: Deals, M&A, and Alliances
Session 5 Tax impact reporting & Digital trust Session 6 Innovation to support the future of health

  

  

Session 1: Industry Outlook: The dynamic new reality

In the thriving life sciences industry, future of health takes the center stage and defines corporate purpose. A purpose that is driven by skilled talent that pushes the boundaries of science to deliver products, services, and changes patients' lives. The workforce and leadership, in this industry, are committed to operating at the highest standards and to comply with complex regulations. In this session, industry leaders and our experts provide insights on:

Welcome to Global Life Sciences Summit

Larry Raff, Global Head of Life Sciences, KPMG International

Healthcare CEO Future Pulse

Anna van Poucke, Global Head of Healthcare, KPMG

The dynamic new reality - Greater China

James Deng, Senior Vice President, Becton Dickinson, General Manager, Greater China.
KPMG host for this session is Colin Yu, National Life Sciences Sector Lead, KPMG China

Innovation ecosystem - Japan

Toshio Fujimoto, General Manager, Shonan Health Innovation Park, Takeda.
KPMG host for this session is Melissa Taylor, Global Lead Partner, Life Sciences Audit, KPMG US

Talent, technology adoption, and flexible workforce

Ayana Champagne, Corporate Vice President, Head of NNI Human Resources, Novo Nordisk
KPMG host for this session is Lynn Gonsor, Managing Director, Advisory Strategy, KPMG US

Digital transformation, innovation and data

Elena Bonfiglioli, GM Healthcare, Strategy Lead Pharma Life Sciences, Microsoft
KPMG host for this session is Mark Gorvin, Global Head of Alliances for Life Sciences, KPMG UK

Back to "Explore the summit"

  

Session 2: Modern technology that is reshaping the life sciences industry

Our recent survey showed the majority of CEOs are driving their organizations to pursue an aggressive digital investment strategy to attain first-mover or fast follower advantage. In this session, life sciences industry experts and technology specialists will provide insights on:

Omnichannel intelligence, optimization and execution to engage with customers and achieve commercial success

Florian Ibe, Global Head of Integrated Multi-Channel Management, Bayer Pharmaceuticals.
KPMG host for this session is Thomas Hillek, Head of Life Sciences, KPMG in Germany

Utilizing automation, analytics and AI to boost efficiency in global supply chain and R&D functions - Part 1

Masashi Kaneko, Vice President, CDO, Mitsubishi Tanabe Pharma Corporation.
KPMG hosts for this session are Justin Hoss, National Technology Leader, Life Sciences, KPMG US

Utilizing automation analytics and AI to boost efficiency in global supply chain and R&D functions - Part 2

Mukesh Rathi, Senior Vice President, CIO & CDO, Dr. Reddy's Laboratories
KPMG host for this session is Justin Hoss, National Technology Leader, Life Sciences,
KPMG US and Mary Rollman, Principal, Advisory, KPMG US

Back to "Explore the summit"

  

Session 3: Social trust in life sciences is vital to help people and planet thrive

The recent ESG movement only enhanced life sciences' continued commitment to social trust. In this session, we will hear from our clients and industry experts on how they are addressing some critical social priorities:

Health for all: The need for innovative Access-to-Medicine programs

Klaus Kunz, Global Head Impact Measurement, Bayer
Shibeshih Belachew, Vice President, Head of Science, Biogen Digital Health Veronique Toully, Global Head of Sustainability, UCB
KPMG host for this panel is Fiona Thomas, Chief Medical Officer, KPMG UK

Diversity, equity, and inclusion in leadership

Molly Joyce, Ethics and Compliance Officer, Global Investigations, AbbVie
KPMG host for this session is John Gitas, Principal, KPMG US

Back to "Explore the summit"

  

Session 4: Dealing in an era of fast evolving innovation: Deals, M&A, and Alliances

Despite the pandemic, the life sciences industries engaged in more deals in 2020 through 2021 than in prior years. In this session, you will hear from our top strategy, legal, and financial partners as they engage luminaries across the life sciences industry to provide insights on:

The outlook on deals, M&A, and transactions in life sciences

Shaun Grady, Senior Vice President, Business Development Operations, AstraZeneca
KPMG host for this session is Richard Sharman, Head of Life Sciences Deal Advisory, KPMG UK

The challenging deal environment and how McKesson is thinking creatively

Monika Brown, Senior Vice President, Corporate Development, McKesson Corporation
KPMG host for this session is Steve Sapletal, Life Sciences Advisory Industry Leader, KPMG US

Strengthening portfolios: When to use acquisitions versus innovative partnerships - Part 1

Peter Cichon, Vice President, Business Development & Licensing, Bayer Pharmaceuticals

Strengthening portfolios: When to use acquisitions versus innovative partnerships - Part 2

Charl van Zyl, Executive Vice President Neurology & Head of Europe/International Markets at UCB
KPMG host for this session is Kristin Pothier, Global Healthcare and Life Sciences Deal Advisory and Strategy Leader, KPMG US

The evolving Federal Trade Commission (FTC) policy - industry predictions and investors perspectives

Arman Oruc, Co-Chair of the Antitrust and Competition Practice at Goodwin
Our KPMG host for both sessions is Jeff Stoll, Principal, National Life Sciences Leader, Strategy, KPMG US

Back to "Explore the summit"

  

Session 5: Tax impact reporting & Digital trust

At a time of renewed concerns about the broader role of companies in society, organizations' reputation for integrity is likely to grow among regulators, customers, and employees. In this session, our clients and industry experts will discuss:

Securing the supply chain and enhancing digital trust.

Michael Wagner, Global Head of Information Security for Supply Chain, Johnson & Johnson
KPMG host for this session is Jonathan Dambrot, Partner at KPMG, Global Solution Leader, KPMG US

Third-party risk management: Mitigating reputational, regulatory, and financial risks

Ronald Goon, Ethics & Business Integrity Head, Sanofi, Greater China
KPMG host for this session is Stephanie Chew, Partner, Governance, Risk and Compliance Services, KPMG China

Digital health platforms

Jan Beger, Senior Director Digital Ecosystem at GE Healthcare
KPMG host for this session is Anusha Foy, Head of Life Science Regulatory Solutions Practice, KPMG UK

Tax impact reporting

Melissa Geiger, Senior Elected Member of the UK Board, Global Lead Tax & Legal, KPMG UK and Loek Helderman, Global Tax Lead KPMG IMPACT, Global Tax & Legal Management Team KPMG Netherlands

Back to "Explore the summit"

  

Session 6: Innovation to support the future of health

Advanced science and cutting-edge technologies are making enormous strides in eliminating and preventing many different diseases. Are you up on the latest? In this session, life sciences industry experts will discuss:

Innovation to support the future of health

Alex Gu, SVP & President for Greater China, Medtronic
KPMG host for this session is Frank Mei, Head of Risk Consulting, Advisory, KPMG China

Executive perspective on orchestrating collaborative innovation, partnerships and alliances to deliver health for all - Part 1

Charl van Zyl, Executive Vice President Neurology & Head of Europe/International Markets at UCB
KPMG host for this session is Kristin Pothier, Global Healthcare and Life Sciences Deal Advisory and Strategy Leader, KPMG US

Executive perspective on orchestrating collaborative innovation, partnerships and alliances to deliver health for all - Part 2

Esther Krofah, Executive Director, FasterCures and Center for Public Health, Milken Institute
Sukumar Nagendran, President, R&D and CMO, Jaguar Gene Therapy
KPMG host for this panel is Alasdair Milton, Managing Director, Healthcare & Life Sciences Strategy, KPMG International

Back to "Explore the summit"

  

Explore last year's summit and our homepage

DNA strand model
Life Sciences

Life Sciences is dedicated to working with internationally leading organizations...